Actively Recruiting
Psilocybin to Treat Depression in Spinal Cord Injury
Led by James J. Peters Veterans Affairs Medical Center · Updated on 2026-05-04
30
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
J
James J. Peters Veterans Affairs Medical Center
Lead Sponsor
B
Bronx Veterans Medical Research Foundation, Inc
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg). The main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure. The investigators will also measure how well people with SCI tolerate the psychedelic experience, and compare responses between the low (5mg), medium (10mg), and high (25mg) doses. Participants will: * Agree to be enrolled in the study for up to 13 months. * Agree to complete the seven (7) visits that are included in the psilocybin-assisted therapy. * Agree to complete follow-up study visits, including in-person visits to the James J Peters VA Medical Center, located in the Bronx, New York and remote visits. * Agree to keep a log of how they are feeling and any change in the frequency or severity of adverse events.
CONDITIONS
Official Title
Psilocybin to Treat Depression in Spinal Cord Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide informed consent
- Spinal cord injury for at least 1 year
- Confirmed diagnosis of depression
- At least 22 years of age at time of consent
- At least 50 kg (110 lbs.) body weight
- Fully independent from ventilatory support (ventilator or diaphragm pacer)
- Fluent in speaking and reading English
- Able to swallow pills
- Agree to have study visits recorded with audio and video
- Agree to release outside medical and psychiatric records
- Able and willing to taper off antidepressant, under clinician supervision
- Agree to use adequate contraceptive methods
You will not qualify if you...
- Unable to give adequate informed consent
- Used psilocybin or another psychedelic within 6 months
- Received Electroconvulsive Therapy (ECT) within 12 weeks
- Used ketamine within 12 weeks
- History of Bipolar I Disorder
- Current eating disorder
- Severe alcohol or cannabis use disorder within the past 6 months
- Illicit drug or prescription drug substance use disorder within 12 months
- Current serious suicide risk
- History of heart attack, aneurysm, or stroke
- Uncontrolled hypertension
- Pregnant or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
James J. Peters Department of Veterans Affairs Medical Center
The Bronx, New York, United States, 10468
Actively Recruiting
Research Team
T
Thomas W Sutor, PhD
CONTACT
D
Dylan C Arnero, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here